Nephrectomy News and Research RSS Feed - Nephrectomy News and Research

Partial nephrectomy offers near equivalent lengths of cancer control compared to radical nephrectomy

Partial nephrectomy offers near equivalent lengths of cancer control compared to radical nephrectomy

Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology. [More]
New market research report on Canadian endoscopic and surgical devices market

New market research report on Canadian endoscopic and surgical devices market

Reportlinker.com announces that a new market research report is available in its catalogue: Canadian Endoscopic and Surgical Devices Market. [More]
Cytoreductive nephrectomy can benefit patients with mRCC

Cytoreductive nephrectomy can benefit patients with mRCC

Patients treated with targeted therapy for metastatic renal cell carcinoma may derive significant survival benefit from cytoreductive nephrectomy, particularly if their initial prognosis is good, study findings indicate. [More]
Partial nephrectomy retains edge over radical nephrectomy in larger renal tumors

Partial nephrectomy retains edge over radical nephrectomy in larger renal tumors

Patients with renal cell carcinoma tumours larger than 4 cm benefit from undergoing elective partial nephrectomy rather than radical nephrectomy surgery, a study has found. [More]
Protein may predict outcome of targeted mccRCC therapy

Protein may predict outcome of targeted mccRCC therapy

Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology. [More]
Partial nephrectomy predicts survival among metastatic RCC patients

Partial nephrectomy predicts survival among metastatic RCC patients

Cytoreductive nephrectomy predicts improved survival among patients with metastatic renal cell carcinoma and synchronous metastases who have received first-line treatment with sunitinib, indicate study findings. [More]
Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Treating patients with nonmetastatic clear-cell renal cell carcinoma with the tyrosine kinase inhibitor axitinib could not only prevent disease progression, but also shrink tumours before surgery, show the results of a phase II trial. [More]
Surgery promising for non-metastatic RCC with thrombus

Surgery promising for non-metastatic RCC with thrombus

Almost half of patients with non-metastatic renal cell carcinoma who have tumour thrombus above the hepatic veins will survive for 5 years after surgery, indicate study results published in The Journal of Urology. [More]

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database. [More]
Renal mass biopsy rates increasing in kidney cancer

Renal mass biopsy rates increasing in kidney cancer

Rates of renal mass biopsy have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data. [More]
Partial nephrectomy may offer younger renal cancer patients survival advantage

Partial nephrectomy may offer younger renal cancer patients survival advantage

Partial nephrectomy may offer younger patients with localized renal cancer a distinct survival advantage compared with the complete removal of the kidney, US research suggests. [More]
Perioperative blood transfusion worsens kidney cancer patients’ survival

Perioperative blood transfusion worsens kidney cancer patients’ survival

Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest. [More]
RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. [More]
More adults are undergoing minimally invasive surgery for diseased kidneys

More adults are undergoing minimally invasive surgery for diseased kidneys

More children, like adults, are undergoing minimally invasive surgery for diseased kidneys, with most of the procedures being performed at teaching hospitals to treat non-cancerous conditions. [More]
Stage and grade dominate RCC outcomes

Stage and grade dominate RCC outcomes

Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma. [More]

Immune marker prognostic after non-clear cell RCC surgery

The preoperative neutrophil-to-lymphocyte ratio is associated with disease-free survival in patients undergoing resection of localized non-clear cell renal cell carcinoma, research shows. [More]
Amendment to renal cancer TNM staging proposed

Amendment to renal cancer TNM staging proposed

Patients with pT3a renal cell carcinoma have markedly worse survival rates if they have both fat invasion and renal vein thrombosis, rather than just one of these factors, a study shows. [More]
Inflammatory marker may highlight aggressive RCC treatment need

Inflammatory marker may highlight aggressive RCC treatment need

Patients with metastatic renal cell carcinoma who have high preoperative levels of the inflammatory marker C-reactive protein may need intensive multimodal treatment to optimize their survival, say researchers. [More]
Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds. [More]

Findings support partial nephrectomy for T1b RCC

Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show. [More]